{"doi":"10.3389/fcvm.2025.1633114","title":"Efficacy and safety of GLP-1 receptor agonists in the treatment of obese patients with chronic heart failure: a meta-analysis","abstract":"<jats:sec><jats:title>Objective</jats:title><jats:p>To investigate the efficacy and safety of Glucagon-Like Peptide-1 Receptor Agonists(GLP-1RAs) (Liraglutide, Semaglutide, Exenatide, Dulaglutide, Lixisenatide, and Tirzepatide) in obese patients with chronic heart failure (CHF).</jats:p></jats:sec><jats:sec><jats:title>Method</jats:title><jats:p>A systematic search was performed in 3 databases (Pubmed, Embase, and Cochrane Library) for articles evaluating the effectiveness and safety of GLP-1RAs (Liraglutide, Semaglutide, Exenatide, Dulaglutide, Lixisenatide, and Tirzepatide) for the treatment of obese patients with CHF from the time the database was created until 5 January 2025. Meta-analyses were performed to evaluate: primary outcomes, including all-cause mortality, cardiovascular mortality, and worsening heart failure events; secondary outcomes, encompassing changes in body weight, Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS), 6-minute walk distance, B-type Natriuretic Peptide (BNP) level, high-sensitivity C-Reactive Protein (hs-CRP) level, and left ventricular ejection fraction (LVEF) level; and safety outcomes, specifically gastrointestinal adverse events and serious adverse events.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>A total of 6 papers were included for Meta-analysis. The primary clinical outcomes: all-cause mortality [OR=0.89, 95% confidence interval (CI): 0.40–2.00, <jats:italic>p</jats:italic> = 0.78], cardiovascular mortality (OR = 0.93, 95% CI: 0.22–4.00, <jats:italic>p</jats:italic> = 0.92) and worsening heart failure events (OR=0.43, 95% CI: 0.30–0.59, <jats:italic>p</jats:italic> &amp;lt; 0.00001); For secondary outcomes, change in body weight (MD = −7.90, 95% CI: −15.44 to −0.35, <jats:italic>p</jats:italic> = 0.04), change in the KCCQ-CSS (MD = 6.81, 95% CI: 6.62–6.99, <jats:italic>p</jats:italic> &amp;lt; 0.00001),change in the 6-minute walk distance (MD = 15.91, 95% CI: 15.36–16.47, <jats:italic>p</jats:italic> &amp;lt; 0.00001), change in the BNP level (MD = −0.13, 95% CI: −0.21 to −0.05, <jats:italic>p</jats:italic> = 0.001), changes in the hs-CRP level (MD = −16.61, 95% CI: −48.53 to 15.31, <jats:italic>p</jats:italic> = 0.31) and change in the LVEF level (MD = −0.91, 95% CI: −2.12 to 0.29, <jats:italic>p</jats:italic> = 0.14). For safety outcomes, gastrointestinal adverse events (OR=0.87, 95% CI: 0.11–7.05, <jats:italic>p</jats:italic> = 0.90) and serious adverse events (OR=0.63, 95% CI: 0.37–1.08, <jats:italic>p</jats:italic> = 0.09).</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>The study results show that GLP-1RAs significantly reduce the risk of worsening heart failure events and improve cardiac function, suggesting that GLP-1RAs are promising treatment options for obese patients with CHF.</jats:p></jats:sec>","journal":"Frontiers in Cardiovascular Medicine","year":2025,"id":625473,"datarank":0.24141568686511508,"base_score":1.6094379124341003,"endowment":1.6094379124341003,"self_citation_contribution":0.24141568686511508,"citation_network_contribution":0.0,"self_endowment_contribution":0.24141568686511508,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":4,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":547214,"name":"Ming Yang","orcid":"0000-0002-1617-9960","position":1,"is_corresponding":false},{"id":157031,"name":"Tianhong Wang","orcid":null,"position":2,"is_corresponding":false},{"id":157034,"name":"Yusi Hua","orcid":null,"position":3,"is_corresponding":false},{"id":1617617,"name":"Huimin Lu","orcid":null,"position":4,"is_corresponding":false},{"id":1617614,"name":"Anna Jia","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Efficacy and safety of GLP-1 receptor agonists in the treatment of obese patients with chronic heart failure: a meta-analysis","abstract":"<jats:sec><jats:title>Objective</jats:title><jats:p>To investigate the efficacy and safety of Glucagon-Like Peptide-1 Receptor Agonists(GLP-1RAs) (Liraglutide, Semaglutide, Exenatide, Dulaglutide, Lixisenatide, and Tirzepatide) in obese patients with chronic heart failure (CHF).</jats:p></jats:sec><jats:sec><jats:title>Method</jats:title><jats:p>A systematic search was performed in 3 databases (Pubmed, Embase, and Cochrane Library) for articles evaluating the effectiveness and safety of GLP-1RAs (Liraglutide, Semaglutide, Exenatide, Dulaglutide, Lixisenatide, and Tirzepatide) for the treatment of obese patients with CHF from the time the database was created until 5 January 2025. Meta-analyses were performed to evaluate: primary outcomes, including all-cause mortality, cardiovascular mortality, and worsening heart failure events; secondary outcomes, encompassing changes in body weight, Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS), 6-minute walk distance, B-type Natriuretic Peptide (BNP) level, high-sensitivity C-Reactive Protein (hs-CRP) level, and left ventricular ejection fraction (LVEF) level; and safety outcomes, specifically gastrointestinal adverse events and serious adverse events.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>A total of 6 papers were included for Meta-analysis. The primary clinical outcomes: all-cause mortality [OR=0.89, 95% confidence interval (CI): 0.40–2.00, <jats:italic>p</jats:italic> = 0.78], cardiovascular mortality (OR = 0.93, 95% CI: 0.22–4.00, <jats:italic>p</jats:italic> = 0.92) and worsening heart failure events (OR=0.43, 95% CI: 0.30–0.59, <jats:italic>p</jats:italic> &amp;lt; 0.00001); For secondary outcomes, change in body weight (MD = −7.90, 95% CI: −15.44 to −0.35, <jats:italic>p</jats:italic> = 0.04), change in the KCCQ-CSS (MD = 6.81, 95% CI: 6.62–6.99, <jats:italic>p</jats:italic> &amp;lt; 0.00001),change in the 6-minute walk distance (MD = 15.91, 95% CI: 15.36–16.47, <jats:italic>p</jats:italic> &amp;lt; 0.00001), change in the BNP level (MD = −0.13, 95% CI: −0.21 to −0.05, <jats:italic>p</jats:italic> = 0.001), changes in the hs-CRP level (MD = −16.61, 95% CI: −48.53 to 15.31, <jats:italic>p</jats:italic> = 0.31) and change in the LVEF level (MD = −0.91, 95% CI: −2.12 to 0.29, <jats:italic>p</jats:italic> = 0.14). For safety outcomes, gastrointestinal adverse events (OR=0.87, 95% CI: 0.11–7.05, <jats:italic>p</jats:italic> = 0.90) and serious adverse events (OR=0.63, 95% CI: 0.37–1.08, <jats:italic>p</jats:italic> = 0.09).</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>The study results show that GLP-1RAs significantly reduce the risk of worsening heart failure events and improve cardiac function, suggesting that GLP-1RAs are promising treatment options for obese patients with CHF.</jats:p></jats:sec>","is_dataset_classified":null,"base_score":1.3862943611198906,"endowment":1.3862943611198906,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"41112222","pmcid":"PMC12533278","openalex_id":"https://openalex.org/W4414784948","authors":[],"funders":[],"total_grants":0,"fwci":0.91,"citation_percentile":0.7164311,"influential_citations":0,"citation_trend":[{"year":2026,"count":3}],"oa_status":"gold","license":"cc-by","oa_locations":[{"url":"https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2025.1633114/pdf","host_type":"journal"},{"url":"https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2025.1633114/pdf","host_type":"publisher"},{"url":"https://www.frontiersin.org/articles/10.3389/fcvm.2025.1633114/full","host_type":"publisher"},{"url":"https://doi.org/10.3389/fcvm.2025.1633114","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/41112222","host_type":"repository"},{"url":"https://doaj.org/article/2974b7b3c7534547a69116dc6466ec65","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/12533278","host_type":"repository"},{"url":"https://europepmc.org/articles/PMC12533278","host_type":"Europe_PMC"},{"url":"https://europepmc.org/articles/PMC12533278?pdf=render","host_type":"Europe_PMC"}],"fields_of_study":["Diabetes Treatment and Management","Heart Failure Treatment and Management","Cardiovascular Function and Risk Factors"],"mesh_terms":[],"keywords":["Heart failure","Agonist","Obesity","Receptor","Heart disease","Clinical trial","Meta-analysis","chronic heart failure","Glp-1 Receptor Agonists","Semaglutide"],"sdg_mappings":[],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-04T06:51:50.339311Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}